A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Enzalutamide (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- 30 Jan 2018 Status changed from suspended to recruiting.
- 08 Nov 2017 Status changed from recruiting to suspended.
- 14 Jun 2016 Planned primary completion date changed from 1 Jan 2020 to 1 Apr 2018.